Navigating the Hospital VAC Process: A Med Device Rep's 2026 Playbook

I've watched more med device reps lose deals to the Value Analysis Committee than to any other single failure point in the pipeline. Every rep I know has this story: the product is clinically superior, the surgeon wants it, the OR staff has already trialed it — and then a VAC packet gets returned with a note that says "insufficient economic justification" or "duplicative with current formulary." Twelve months of work, gone.

Here's what this playbook is really about — not losing that deal. It covers what the hospital VAC process actually is in 2026, why cold submissions still fail even when the clinical case is airtight, and the five-play adaptation I've seen top reps use to walk into VAC review with a surgeon champion, three peer-hospital reference sites, and an executive sponsor already lined up.

For the broader relationship framework this playbook sits inside, see the parent glossary: Warm Introductions in Medical Device Sales.

What a hospital Value Analysis Committee actually does

A Value Analysis Committee (VAC) is a hospital's cross-functional gatekeeping body for every new medical device, implant, consumable, and capital purchase that enters the facility. Per Symplr's operational guide, the VAC's job is to balance cost-effectiveness with clinical outcomes, ensuring patient care is both high-quality and financially sustainable. In practice, it's the last approval a rep needs before the product hits the OR schedule — and the first one that gets skipped by cold submissions.

Composition. A typical VAC has 8-15 voting members drawn from:

• Physicians (service line chief + one or two practicing surgeons in the specialty)
• Nursing (usually the OR nurse manager or clinical educator)
• Supply chain (director of materials management or category manager)
• Finance (VP finance or a CFO delegate for high-dollar items)
• Value analysis leader (the VAC chair, often with a nursing or supply chain background)
• Biomed engineering (for anything electronic, implantable, or requiring service contracts)
• Infection control (for anything touching sterile field or reprocessing)
• Pharmacy (for combination products or drug-device)
• IT (increasingly, for connected devices and EHR integration)
• Risk management or legal (for higher-risk classes)

At larger IDNs the structure duplicates: each hospital has a local VAC, and a system-level VAC or "clinical council" reviews anything above a dollar threshold or with cross-facility impact.

Decision criteria. Every VAC scores submissions across three dimensions:

1. Clinical effectiveness — peer-reviewed evidence, ideally RCTs, that the device is at least as good as the incumbent and preferably better on a specific outcome (infection rate, revision rate, length of stay, complication rate).
2. Financial impact — total cost of ownership vs. incumbent, GPO tier, reimbursement coverage, expected utilization, and any offsetting savings (fewer OR minutes, fewer readmissions, shorter LOS).
3. Operational fit — does it work with existing workflow, does it require training or capital investment, does it duplicate existing formulary, does the current vendor relationship allow it?

Per Provyx and Accretive Edge's summaries of the modern VAC decision framework, committees now expect clinical study data, regulatory documentation, pricing analysis, and a comparison with existing solutions in the submission packet — not as supporting material but as the packet itself.

Timeline. This is where reps lose the most time. A VAC review runs on the committee's cadence, not the rep's. UCLA Health's academic-center process can turn a straightforward consumable in six to eight weeks. A large IDN reviewing a Class II implantable typically takes three to six months. Anything requiring a formal economic analysis, a clinical trial period, or system-level approval routinely extends to nine to twelve months. Many VACs meet monthly or quarterly, so a missed submission window adds 30 to 90 days by default.

The functional reality: assume 6-9 months for a mid-complexity submission and 12 months for capital equipment or high-cost implants. Anything faster is a bonus; anything slower means something went wrong.

Why cold submissions fail

Here's the pattern I keep seeing in rejected VAC submissions. The stories cluster into five failure modes:

1. No clinical champion in the room. The VAC's clinical members carry disproportionate weight — a supply chain director rarely overrides a surgeon on a clinical question, and a CFO rarely overrides a service line chief on a strategic priority. If no committee member has personally trialed the device, spoken to a peer at another institution, or agreed to sponsor the submission, the packet gets tabled. Symplr's operational guide puts it plainly: the strongest VAC submissions arrive with a named physician sponsor and evidence of clinical demand.

2. No peer-hospital reference. VACs are conservative by design. The question that kills more submissions than any other is "who else in our peer group is using this?" If the answer is "no one" or "we can share a case study from a hospital nobody's heard of," the committee has cover to defer. A named peer academic center, a competing IDN in the same market, or a hospital in the same GPO tier is often the single piece of evidence that unblocks review.

3. Weak economic case. Clinical evidence gets you clinical member support. Economic evidence gets you supply chain and finance. Reps who submit clinical data without a total-cost model, a utilization forecast, and a comparison to incumbent's GPO pricing get a polite "come back with financials." That round trip alone adds 60-90 days.

4. Submission arrives after the agenda closes. Every VAC has a submission cutoff — often two to four weeks before the meeting. Reps who submit late get pushed to the next cycle, which at a quarterly cadence means a full quarter's delay. Reps who submit without pre-briefing the chair often get pulled from the agenda for "insufficient prep."

5. No executive sponsor for high-dollar items. Anything requiring capital budget approval, service line investment, or GPO contract exception needs an executive sponsor — a service line VP, a CMO, a CFO delegate, or the chief supply chain officer. Cold submissions rarely have one. The VAC will defer to executive review, and the executive has no context to advocate.

The five plays below are structured around fixing each failure mode before the submission goes in.

The five-play VAC navigation adaptation

The Boomerang warm-introduction framework runs on five plays. Adapted specifically for VAC navigation, each play targets one of the failure modes above.

Play 1 — Discover the clinical champion inside the account

Before drafting a VAC packet, run a path-discovery pass on the target hospital. The goal isn't a submission — it's identifying which of the account's practicing surgeons, service line chiefs, or clinical educators is closest in specialty, procedure volume, and academic profile to a champion surgeon you already work with elsewhere.

The mechanics: query your division's shared connector graph for any relationship — direct or one-hop — into the target account's clinical members. In Boomerang, that means matching your reps', your executive team's, and your existing customer champions' networks against the target hospital's roster. A high-value output looks like: "Dr. Amara Patel, Director of Structural Heart at [target IDN], trained under Dr. Kim at your existing account, and Dr. Kim has already published with her on TAVR outcomes."

That's a clinical champion candidate — someone with an existing peer relationship to a surgeon who already uses your device. The first case observation goes through that path, and the VAC submission is drafted with that surgeon named as sponsor.

Play 2 — Name-drop peer hospitals already using

Once a clinical champion is identified, the second play front-loads the submission packet with peer-hospital references. The rule of thumb: three named institutions in the same tier as the target, with at least one in the same GPO or IDN affiliation, and at least one with published outcomes data.

Peer references do two things inside a VAC. First, they neutralize the "who else uses this?" question that kills mid-cycle reviews. Second, they give the clinical members a phone tree — if a service line chief on the VAC wants a second opinion, they can call their counterpart at a named peer institution rather than trust the rep's summary. That direct-verify capability, more than the packet itself, converts skeptical committee members into neutral ones.

The name-drop only works if the reference sites are real, current, and reachable. Fabricating or overstating adoption is a career-ending mistake in med device — hospital clinical networks are small enough that every reference will get verified within a week.

Play 3 — Warm intro to the VAC chair via the champion surgeon

In my view, the single highest-leverage moment in the whole VAC cycle is the pre-submission meeting with the VAC chair. [I've seen reps skip this and pay for it every time — cold submissions to unfamiliar chairs are the fastest path to a "please revise" letter, and that letter costs you a full review cycle.] Chairs — usually the value analysis leader or a supply chain director — control the agenda, the review pace, and the packet standards. Reps who show up cold get 20 minutes of politeness and a form. Reps who show up warm-introduced by a service line chief on the committee get 45 minutes of substantive pre-briefing, edits to the packet before submission, and a fast-track slot on the next agenda.

The play: use the champion surgeon identified in Play 1 to warm-introduce the rep to the VAC chair. The forwardable ask is short — "I'm reviewing [device] for our next case series and would value a pre-brief with the VAC on the submission requirements." Boomerang drafts that ask in the champion's voice, sends the moment the champion approves, and logs the intro against the target account's timeline.

The pre-brief itself is where the rep learns the account-specific quirks that don't appear in any public documentation: this VAC weights infection outcomes over cost, that VAC won't consider anything without a 90-day trial, this chair wants a one-page executive summary at the top of the packet, that IDN routes capital items above $250k to a separate system-level council. None of that is on the website. All of it decides the outcome.

Play 4 — Customer Network Activation: happy surgeons vouching to peers

Every existing champion surgeon knows three to seven counterparts at other institutions who would take their call about a device they're satisfied with. Systematically converting that latent network into VAC-ready references is the Customer Network Activation play, and it's the single biggest source of high-conviction peer references in the med device pipeline.

The mechanics for VAC navigation specifically: 60 to 90 days after a champion surgeon has completed a positive case series — long enough to have real outcomes, short enough that the enthusiasm hasn't cooled — the rep asks for three named peer introductions at three specific target hospitals. Not "let me know who might be interested" (which produces nothing). Named surgeons, named hospitals, drafted intro asks that the champion can forward with a single click.

Each of those three introductions typically produces one first case observation, one active VAC discussion, and 0.3 to 0.5 new champion surgeons. Across a division of 20 reps activating ten champions each per year, that's 600 peer-referenced VAC submissions annually — enough to seed every meaningful account in most territories.

Boomerang runs this play automatically: it tracks 60-day post-implant milestones, drafts the peer-intro ask in the champion's voice with case data pre-populated, and logs which peer introductions produced VAC submissions. It's the closest thing in med device to a compounding pipeline engine.

Play 5 — Executive activation: regional VP calling the hospital CFO

Any VAC submission involving capital equipment, high-cost implants, or GPO contract exceptions needs an executive sponsor inside the hospital. That sponsor is usually the service line VP, the CMO, or the CFO — depending on which pain point the device solves. Reps rarely have direct C-suite access. Their executives do.

The play: for the top 10 to 15 target IDNs per quarter, identify which of your executive team members (Regional VP of Sales, VP of Clinical Affairs, CEO, Chief Medical Officer, Medical Advisory Board surgeons, board members with health-system operating backgrounds) can warm-introduce to the target's CFO, CMO, or service line VP. Draft a 90-second call script — not a pitch, a peer-level conversation about a clinical program the target is standing up. Book the call.

Executive activation is a monthly rhythm, not a one-time event. Twenty minutes from a regional VP per month, targeting three CFO or CMO conversations, produces two to three executive-level sponsors per quarter — which materially changes the outcome on high-dollar VAC reviews. The ROI on executive time is measured in eight-figure IDN contracts.

The 30-day pre-VAC prep checklist

The 30 days before a VAC submission is where the deal is made or lost. Working backward from the submission cutoff:

Days -30 to -21: Champion and reference lock-in. - Confirm the clinical sponsor on the committee (Play 1) - Confirm three peer-hospital references with contact permission (Play 2) - Pull two to three peer-reviewed papers plus one published case series that support the primary clinical claim - Draft the clinical outcomes summary — one paragraph, three data points, one comparison to incumbent

Days -21 to -14: Economic case. - Build a total-cost-of-ownership model for the target hospital's volume assumptions - Pull GPO tier pricing and confirm current contract status with the target's GPO - Model reimbursement coverage using the target's payer mix - Draft the one-page executive financial summary

Days -14 to -7: Executive and chair alignment. - Book the VAC chair pre-brief (Play 3) — bring the draft packet, ask for edits - Confirm the executive sponsor and align on the ask (Play 5) - Send the champion surgeon a copy of the packet for review; incorporate feedback - Confirm the submission cutoff, meeting date, and any format requirements

Days -7 to 0: Submit and pre-work the committee. - Submit the completed packet - Send a short courtesy note to each named committee member — not a pitch, an "available for questions before the meeting" note - Prep the champion surgeon and executive sponsor for the meeting itself if they're attending - Confirm the follow-up path: who owns the trial period, the vendor onboarding, and the first-case scheduling

Metrics that tell you the engine is working

Here's what I've seen at Boomerang customers running this well — three metrics matter more than the rest:

• VAC-submitted per rep per quarter. Best-in-class divisions run 3-5 fully warm-supported VAC submissions per rep per quarter. Anything below 2 is a network-activation problem, not a rep problem.
• VAC-approved rate. The industry average for cold submissions is 30-40%. Warm submissions with a clinical champion, three peer references, and an executive sponsor routinely hit 65-75%. If your division is below 50%, the packet quality is fine — the pre-work is missing.
• Days-to-approval (from first champion contact to VAC decision). Cold: 180-360 days. Warm with all five plays running: 90-150 days. Every 30 days shaved off the timeline compounds into faster revenue realization and more capital cycles hit per fiscal year.

Two secondary metrics worth tracking: peer-reference-conversion rate (how many peer-hospital references produce a first case at the target), and executive-sponsor-attach rate (how many high-dollar submissions have a named executive sponsor at submission time).

Tools worth having in the stack

Boomerang — the warm-intro orchestration layer. Maps every warm path from your reps, champion surgeons, executive team, MAB, and professional partners into your target IDN and ASC accounts. Automates the Play 1 through Play 5 mechanics: path discovery, drafted intro asks, champion network activation, and executive activation rhythms. Where legacy relationship intelligence tools stop at the graph, Boomerang closes the loop from signal to VAC-ready submission.

Symplr — VAC-side workflow and product evaluation tooling. Widely deployed at IDNs and health systems as the platform of record for value analysis workflow. Understanding how Symplr structures submissions at your target accounts — required fields, evidence categories, review cadence — meaningfully improves packet quality. Symplr also publishes benchmarking data on VAC decision timelines and criteria.

Veeva CRM or Salesforce Health Cloud — the life-sciences CRM layer for logging HCP interactions, Sunshine Act reporting, and sample tracking. Boomerang sits on top of these to add the warm-intro and signal layer.

Definitive Healthcare or IQVIA — provider intelligence for target account mapping, surgeon volume data, and IDN affiliation. Useful for building the Play 1 candidate list.

The pattern: CRM plus healthcare intelligence plus VAC workflow (Symplr) plus warm-intro orchestration (Boomerang). Each layer is necessary, none is sufficient alone.

Case scenario: Class III implantable, IDN target, 90-day approval

A synthetic composite drawn from patterns we've seen across implantable device categories:

A structural heart device rep is targeting a 12-hospital regional IDN in the Midwest. Historical baseline for this category at this IDN: 9-12 month VAC cycle, ~45% approval rate on first submission, average two rounds of revision before decision.

Play 1 (week 1). Rep queries the division's connector graph. Match: Dr. James Okafor, Chief of Structural Heart at the target IDN's flagship hospital, trained under Dr. Reyes at an existing customer account. Dr. Reyes has completed 47 cases with the device over 18 months and is a public reference.

Play 4 (week 2). Rep asks Dr. Reyes for a peer intro to Dr. Okafor. Boomerang drafts the note in Dr. Reyes' voice, referencing the case volume, one specific outcome (35% reduction in mean OR time in the last cohort), and the request. Dr. Reyes approves and forwards. Dr. Okafor books a call for week 3.

Play 2 (weeks 3-4). Rep confirms three peer references at similarly-sized IDNs in the Midwest region, including one within the same GPO tier. Two have published outcomes; one is willing to host a site visit.

Play 5 (week 4). Regional VP of Sales warm-introduced to the IDN's Chief Medical Officer through a shared board relationship. 30-minute call books for week 6. Framed as a peer-level conversation about the IDN's structural heart program growth strategy, not a pitch.

Play 3 (week 5). Dr. Okafor introduces the rep to the VAC chair (a nursing-background value analysis leader). Pre-brief happens in week 6. The chair flags two packet issues: economic model needs the IDN's specific payer mix, and the committee will require a 60-day trial period with three named implanters.

Weeks 7-10. Rep revises the packet with the chair's guidance. Trial period scheduled. Executive sponsor (CMO) confirms attendance at the VAC meeting.

Week 12. VAC meeting. Submission approved with the 60-day trial condition. Trial begins immediately.

Week 24. Trial completes with outcomes matching the peer-reference data. System-level approval issued.

Total elapsed time: ~90 days from first champion contact to VAC approval; ~180 days including the trial period to system-wide approval. Historical baseline for the account: 270-360 days. Warm-path execution compressed the cycle by 60-70%.

Frequently asked questions

How long does the hospital VAC process actually take in 2026? For a mid-complexity consumable or single-use device with a strong clinical case, 6-9 months at a large IDN and 6-8 weeks at some academic centers like UCLA. Capital equipment, high-cost implants, or anything requiring formal economic analysis routinely runs 9-12 months. Warm-path submissions with a clinical champion, peer references, and an executive sponsor typically compress the timeline by 40-60% by eliminating the "come back with more data" round trips.

What does a VAC actually score submissions on? Three dimensions: clinical effectiveness (peer-reviewed evidence versus the incumbent), financial impact (total cost of ownership, GPO tier, reimbursement, utilization), and operational fit (workflow, training, duplication with existing formulary). Cold submissions often over-index on clinical and under-invest in economic modeling and operational fit, which is why they get returned rather than rejected outright.

Do I need a physician champion inside the account to get through VAC? Effectively yes for anything clinical. The VAC's physician members carry disproportionate weight on clinical questions, and the committee treats "no internal clinical sponsor" as a signal that the product doesn't have clinical demand. The exception is a pure commodity with a clear cost-parity swap and no clinical differentiation — those can sometimes route through supply chain alone. Everything else needs a named surgeon or service line chief sponsoring the submission.

How do I get warm-introduced to a VAC chair when I've never worked with the account? Through the clinical champion. VAC chairs will take meetings from physicians on their own committee much faster than from vendors. The play is to identify the clinical champion first (Play 1), get warm-introduced to them (Play 3 or 4), and then have the champion introduce the rep to the chair. Cold rep-to-chair outreach converts at a fraction of the rate.

What's the difference between running VAC navigation manually versus through a platform like Boomerang? Manually, each rep runs their own connector graph, drafts their own peer-intro asks, tracks their own signals, and relies on memory for champion activation rhythms. That works up to a point — usually until the division has more than 10 reps or 100 target accounts. Boomerang turns the whole motion into a channel: pooled network graph across the division, automated path discovery, drafted intro requests in the connector's voice, champion 60-day activation reminders, executive activation rhythms, and closed-loop tracking from signal to VAC decision. The manual version produces 1-2 warm submissions per rep per quarter; the platform version produces 3-5.

Related reading

• Warm Introductions in Medical Device Sales: How Top Reps Prospect Hospitals, IDNs and ASCs — the parent glossary and full warm-intro framework
• Customer Network Activation: The 2026 Playbook — Play 4 in depth, the compounding engine behind peer references
• Medical Device Sales Tools: The 2026 Stack — the full CRM, intelligence, VAC workflow, and warm-intro layer
• How to Sell Medical Devices to Hospitals: A 2026 Guide — the end-to-end account motion, VAC to implant

Build the warm-intro engine behind your VAC pipeline

Boomerang is the warm-intro orchestration layer for medical device sales teams navigating the hospital VAC process. It maps every warm path from your reps, champion surgeons, executive team, and Medical Advisory Board into your target IDN and ASC accounts — then automates the five plays that turn a cold submission into a champion-backed, peer-referenced, executive-sponsored VAC packet. The pipeline motion your division has been running by hand, at the scale of every account in your territory. Book a 15-minute walkthrough →